100% of Patients Achieved Remission Within 30 Days in Cohort 1 of the Mipletamig RAINIER Dose Optimization Trial for Frontline AML Patients, Trial Enrollment Continues
Promising Data, including a 59% Stable Disease Rate, in ALG.APV-527 Phase 1 Trial for the Treatment of Multiple Solid Tumors Makes the Case for Continued Development of First-in-Class Anti-Cancer Agent
Read MoreReports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing
Reports full-year revenues of $3.2 billion, GAAP net loss of $(3.6) billion and GAAP diluted EPS of $(9.28)
Expects 2025 revenue range of $1.5 to 2.5 billion andending cash balance of approximately $6 billion
Submitted three investigational mRNA products for regulatory approval, including Moderna's next-generation COVID vaccine, RSV vaccine for high-risk adults aged 18 to 59, and flu/COVID combination vaccine
Read MoreNet income of $0.8 million
Adjusted EBITDA1 of $1.3 million
Pediatric Portfolio net revenue up 86% sequentially
First quarterly sequential prescription increase for both ADHD and Pediatric portfolios since Q2 fiscal 2023
$20.4 million cash balance at December 31, 2024
Company to host conference call and webcast today, February 12, 2025, at 4:30 p.m. Eastern time
Read MoreTrent Ward, Ali Ahmad and Mohammed Iqbal Unpack Tailwinds and Major Opportunities in Fragmented Health & Wellness Market During Fireside Chat
Company Also Provides Shareholder Update
Read More
The "smart" pill bottle provides physicians and pharmacists with a solution that ensures patients adhere to medications as prescribed, preventing medical problems such as prolonged illness, increased hospitalization and overdosing.
Read MoreTRNR is expected to generate more than $50M in revenue in 2025 on a pro forma basis and achieve EBITDA profitability in H2 ‘25
Sportstech is founder-led, having achieved profitability and scale without raising capital and has successfully sold equipment to almost 3 million customers since 2012
TRNR Listing and global presence to help Sportstech accelerate growth beyond core markets, most notably the US; Sportstech's scaled, profitable business to drive step-change for TRNR top and bottom lines
Transaction delivers on previously-announced LOI, combines highly complementary businesses to create a scaled, international operation anchored in the US and Germany, the #1 and #2 fitness markets globally
Deal - TRNR's second within 12 months - advances its strategy for building shareholder value through accretive acquisitions of profitable, growth businesses in the fragmented global health & wellness market
TRNR CEO to discuss transaction at 2025 Connected: Health & Fitness Summit today in Los Angeles
Read MoreIntroduces the concept of "Evidence Fluency" as a solution to the current crisis and a path towards improving healthcare overall
Read More
MMJ is currently engaged in litigation with the Drug Enforcement Administration (DEA). The company contends that the DEA has obstructed domestic cannabis research despite the Right To Try and the Medical Marijuana Research Expansion Act. MMJ accuses the DEA of bias in restricting MMJ to cultivate its proprietary marijuana cultivars necessary for research and pharmaceutical drug manufacturing. A pending federal court ruling in Rhode Island will set a significant precedent, challenging DEA authority and potentially easing regulatory barriers for MMJ's future cannabinoid drug development.
Read MoreA wholly owned subsidiary of Nitches Inc. (OTC:NICH), InTheZone Labs is at the forefront of a rising health movement as customers uncover powerful De-Aging effects from its premium nootropic formulations.
Read MoreMagdalena aiming to submit Investigational New Drug (IND) application in 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as ADHD and schizophrenia, with 1-2 additional IND applications filed in late 2025/early 2026
Read MoreRevenues increased 14% for the quarter compared to prior year and 13% year-to-date
Positive cash flow from operations for the quarter with $5.2 million of cash at December 31, 2024
Year-to-date net loss decline of $1.1 million
